PT - JOURNAL ARTICLE AU - Dmitry Nagatkin AU - Alexandr Zhestkov AU - Julia Bogdanova AU - Olga Nagatkina TI - The impact of sublingual allergen-specific therapy on asthma control and quality of life DP - 2014 Sep 01 TA - European Respiratory Journal PG - P3475 VI - 44 IP - Suppl 58 4099 - http://erj.ersjournals.com/content/44/Suppl_58/P3475.short 4100 - http://erj.ersjournals.com/content/44/Suppl_58/P3475.full SO - Eur Respir J2014 Sep 01; 44 AB - The sublingual allergen-specific therapy (SLIT) is the most perspective method of pathogenic therapy of allergic asthma. Unfortunately, there are very few studies concerning the influence of SLIT on asthma control.The aim of our work was to find out whether SLIT improves notably the asthma control and quality of life of patients with allergic asthma and sensitization to pollen of trees.We enrolled 37 patients with mild or moderate asthma, each of them had a skin prick tests positive to pollen of a birch, alder or hazel. Patients were divided into two groups, similar in initial asthma control level, asthma severity, gender and sex: the 1st group (18 patients) - received SLIT to birch, alder and hazel allergens and the 2nd group - did not have this benefit. We evaluated the control level by ACT test and ACQ-5 test, quality of life by SF-36 and mean dose of inhaled corticosteroids (ICS) before and after SLIT. We used a standardized index of reactivity allergens.We observed significant difference in the average dose of ICS before and after the research at the 1st group: 513.15 mg per day initially and 355.22 mg per day after SLIT (p<0.05). Comparative analysis showed significant differences between groups in FEV1 data, ACQ-5 and ACT™ test results. Patients of the 2nd group had significant differences in the FEV1, results of ACQ-5 and ACT™ tests and average ICS doses in comparison with the first group.We observed significant differences between two groups in all parameters of life quality level (p<0.05).Conclusion: We demonstrated a marked positive affect of SLIT on asthma control and life quality level of patients with sensitization to pollen of trees and mild or moderate asthma.